Bladder transitional cell carcinoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder transitional cell carcinoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long-Term Study for Cancer Patients Using Atezolizumab Therapy https://clinicaltrials.eu/trial/long-term-study-for-cancer-patients-using-atezolizumab-therapy/ Wed, 29 Apr 2026 14:57:00 +0000 https://clinicaltrials.eu/trial/long-term-study-for-cancer-patients-using-atezolizumab-therapy/ This clinical trial is focused on studying the effects of a medication called atezolizumab, which is marketed under the name Tecentriq. The study is designed for patients who have been previously involved in a study sponsored by Genentech or F. Hoffmann-La Roche Ltd. The main goal is to provide continued access to atezolizumab-based therapy for patients who were receiving it in a previous study and do not have access to it locally. The study primarily involves patients with cancer, although future studies may include other types of cancer.

Participants in this study will continue to receive atezolizumab or a comparator agent, which is another treatment used for comparison, if they were benefiting from it in the previous study. The treatment is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein. The study will observe patients over a long period to monitor their health and any side effects they may experience. This includes tracking any serious adverse events, which are unexpected medical problems that occur during treatment, and their severity.

The study will also look at the time from when patients start the treatment to when they may pass away from any cause, specifically for those who were part of a previous study called IMpower133. This trial aims to ensure that patients who were benefiting from atezolizumab can continue their treatment safely and effectively, while also gathering important information about the long-term effects of the medication.

]]> Study on Durvalumab with Trimodality Therapy for Patients with Muscle-Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-durvalumab-with-trimodality-therapy-for-patients-with-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 14:30:32 +0000 https://clinicaltrials.eu/trial/study-on-durvalumab-with-trimodality-therapy-for-patients-with-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as muscle-invasive bladder cancer. The trial is investigating the use of a treatment called Durvalumab, which is also known by its code name MEDI4736. Durvalumab is a medication that is given as a solution through an infusion, which means it is administered directly into the bloodstream. The purpose of the study is to determine if adding Durvalumab after standard treatment can improve the time patients remain free from cancer.

Participants in the study will have already completed a standard treatment approach called trimodality therapy, which includes surgery, chemotherapy, and radiation therapy. After this initial treatment, participants will be randomly assigned to receive either Durvalumab or no additional treatment, which is referred to as surveillance. The study will monitor participants over time to see if Durvalumab helps in preventing the return of cancer or the development of new cancer.

The study aims to assess the effectiveness of Durvalumab in improving outcomes for patients with muscle-invasive bladder cancer. It will also look at other factors such as the control of cancer in the bladder area, overall survival rates, and the impact on quality of life. The trial is expected to continue until early 2026, with participants being closely followed throughout the study period.

]]>